Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel bought 2,000 shares of the company's stock in a transaction dated Thursday, January 2nd. The stock was bought at an average price of $11.97 per share, for a total transaction of $23,940.00. Following the acquisition, the chief executive officer now directly owns 5,543,702 shares of the company's stock, valued at approximately $66,358,112.94. This represents a 0.04 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Snehal Patel also recently made the following trade(s):
- On Monday, December 30th, Snehal Patel bought 3,200 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $11.12 per share, with a total value of $35,584.00.
Greenwich LifeSciences Stock Performance
NASDAQ:GLSI traded up $0.23 during trading on Monday, reaching $13.11. The company's stock had a trading volume of 44,060 shares, compared to its average volume of 43,153. Greenwich LifeSciences, Inc. has a 12 month low of $8.00 and a 12 month high of $21.44. The firm has a market cap of $172.33 million, a price-to-earnings ratio of -16.39 and a beta of 1.66. The firm has a 50 day moving average of $13.20 and a 200-day moving average of $14.17.
Hedge Funds Weigh In On Greenwich LifeSciences
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Garden State Investment Advisory Services LLC purchased a new position in Greenwich LifeSciences in the 3rd quarter valued at approximately $253,000. Barclays PLC grew its position in shares of Greenwich LifeSciences by 323.3% in the third quarter. Barclays PLC now owns 8,560 shares of the company's stock valued at $123,000 after purchasing an additional 6,538 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Greenwich LifeSciences by 4.6% during the 3rd quarter. Geode Capital Management LLC now owns 133,550 shares of the company's stock worth $1,919,000 after purchasing an additional 5,861 shares in the last quarter. State Street Corp boosted its stake in Greenwich LifeSciences by 4.4% in the 3rd quarter. State Street Corp now owns 71,408 shares of the company's stock worth $1,026,000 after purchasing an additional 3,005 shares during the period. Finally, Rhumbline Advisers purchased a new position in Greenwich LifeSciences during the 2nd quarter valued at about $117,000. Institutional investors own 4.16% of the company's stock.
About Greenwich LifeSciences
(
Get Free Report)
Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Featured Articles
Before you consider Greenwich LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Greenwich LifeSciences wasn't on the list.
While Greenwich LifeSciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
